Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) EBITDA Margin (2016 - 2025)

International Stem Cell (ISCO) has disclosed EBITDA Margin for 16 consecutive years, with 6.82% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin rose 43.0% to 6.82% in Q2 2025 year-over-year; TTM through Jun 2025 was 0.95%, a 566.0% increase, with the full-year FY2024 number at 0.75%, up 776.0% from a year prior.
  • EBITDA Margin was 6.82% for Q2 2025 at International Stem Cell, up from 10.1% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.82% in Q2 2025 to a low of 34.2% in Q1 2021.
  • A 5-year average of 9.02% and a median of 6.37% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 3544bps in 2022, then crashed -2496bps in 2023.
  • International Stem Cell's EBITDA Margin stood at 17.53% in 2021, then soared by 114bps to 2.51% in 2022, then plummeted by -994bps to 22.45% in 2023, then skyrocketed by 109bps to 2.09% in 2024, then skyrocketed by 227bps to 6.82% in 2025.
  • Per Business Quant, the three most recent readings for ISCO's EBITDA Margin are 6.82% (Q2 2025), 10.1% (Q1 2025), and 2.09% (Q4 2024).